Mechanism of Action
GIP Receptor Agonism
Last updated
The compound activates the receptor for glucose-dependent insulinotropic polypeptide, the other main incretin hormone released from the gut after a meal. GIP receptors are found on pancreatic beta cells, on fat tissue and in the brain. In this database the mechanism appears almost entirely as one half of dual-agonist molecules that also act at the GLP-1 receptor.
Flagged for specialist review
This entry describes something contested, or asserts a detail we have not been able to confirm against a settled source. It is published rather than withheld, with the flag visible, because an entry you can weigh beats a gap you cannot see.
Why it matters here
Where a record names both GIP and GLP-1 action, the evidence for the combination is not the sum of the evidence for each part, so a dual-agonist claim needs its own graded row.
What it is not
The direction here is genuinely unsettled. Both GIP receptor agonists and GIP receptor antagonists have been investigated for weight-related effects, and the literature has not resolved why opposite interventions appear to point the same way. Treat any confident mechanistic story about GIP as a hypothesis. GIP is also not GLP-1, despite both being incretins.
Also called
- gip agonist
- gip receptor agonism
- glucose-dependent insulinotropic polypeptide agonism
GIP originally stood for gastric inhibitory polypeptide and was later renamed glucose-dependent insulinotropic polypeptide. Both expansions name the same hormone, and older sources use the first.
Compounds carrying this term
None on file yet. This term is in the controlled vocabulary but no compound record currently uses it — which is a statement about our coverage, not about the term.